News
PLX
2.300
-3.36%
-0.080
Protalix: Elfabrio Struggles Against Oral Competition
Seeking Alpha · 1d ago
Weekly Report: what happened at PLX last week (0406-0410)?
Weekly Report · 3d ago
Weekly Report: what happened at PLX last week (0330-0403)?
Weekly Report · 04/06 09:39
Protalix Earnings Call: EU Win, Cash Boost, Trade-Offs
TipRanks · 04/02 00:28
Weekly Report: what happened at PLX last week (0323-0327)?
Weekly Report · 03/30 09:39
Protalix Revenue Miss Overshadowed By Milestone-Backed 2026 Guidance
Seeking Alpha · 03/24 18:42
Weekly Report: what happened at PLX last week (0316-0320)?
Weekly Report · 03/23 09:37
Protalix BioTherapeutics Price Target Maintained With a $12.00/Share by HC Wainwright & Co.
Dow Jones · 03/19 12:25
HC Wainwright & Co. Reiterates Buy on Protalix BioTherapeutics, Maintains $12 Price Target
Benzinga · 03/19 12:15
Protalix: EU Approval and Commercial Tailwinds for Elfabrio Underscore Undervalued Upside
TipRanks · 03/19 10:25
Protalix Stock Down As FY25 Results Show Net Loss, Fabry Milestones Boosts Outlook
NASDAQ · 03/19 01:19
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 03/18 17:06
Wednesday Sector Laggards: Precious Metals, Biotechnology Stocks
NASDAQ · 03/18 15:59
Protalix targets $78M–$83M 2026 revenue with EU milestone, advancing PRX-115
Seeking Alpha · 03/18 14:13
Earnings Scheduled For March 18, 2026
Benzinga · 03/18 11:11
Protalix BioTherapeutics Expects FY26 Total Revenue To Range From ~$78M To $83M Including $25M Milestone Which Protalix Is Entitled To From Chiesi
Benzinga · 03/18 11:01
Protalix BioTherapeutics Q4 EPS $(0.06) Misses $0.04 Estimate, Sales $9.300M Miss $16.918M Estimate
Benzinga · 03/18 10:57
Protalix BioTherapeutics misses top-line and bottom-line estimates; gives FY26 outlook
Seeking Alpha · 03/18 10:54
Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results
PR Newswire · 03/18 10:50
Here are the major earnings before the open Wednesday
Seeking Alpha · 03/17 22:00
More
Webull provides a variety of real-time PLX stock news. You can receive the latest news about Protalix Biother through multiple platforms. This information may help you make smarter investment decisions.
About PLX
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of uncontrolled gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase) - a chemically modified enzyme to treat uncontrolled gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate. Its product includes Elelyso and Elfabrio. Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease.